Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Last week, Sanofi and Regeneron reported the failure of a phase 3 trial of their chronic obstructive pulmonary disorder (COPD) candidate itepekimab. In February, Sanofi revealed a phase 3 trial of ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Regeneron Pharmaceuticals declined by 16.7 percent last week as investors sold off positions amid the surprising failure of ...

Sanofi also said today that it is expanding ... Meanwhile, the clinical trial programme for IL-33 inhibitor itepekimab is being expanded into CRSwNP, along with COPD and bronchiectasis.

Sanofi said this morning that its pipeline ... an IRAK4 degrader for atopic dermatitis, IL-33 inhibitor itepekimab for chronic obstructive pulmonary disease (COPD), and vaccines against acne ...